June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Sustained Delivery of Travoprost from a Biodegradable Hydrogel Punctum Plug for the Treatment of Glaucoma
Author Affiliations & Notes
  • Abbe Miller
    Ocular Therapeutix, Inc., Bedford, MA
  • Charles Blizzard
    Ocular Therapeutix, Inc., Bedford, MA
  • Amar Sawhney
    Ocular Therapeutix, Inc., Bedford, MA
  • Michael Bassett
    Ocular Therapeutix, Inc., Bedford, MA
  • Peter Jarrett
    Ocular Therapeutix, Inc., Bedford, MA
  • Arthur Driscoll
    Ocular Therapeutix, Inc., Bedford, MA
  • Monica O'Connor
    Ocular Therapeutix, Inc., Bedford, MA
  • Doug Molla
    Ocular Therapeutix, Inc., Bedford, MA
  • Steve Takach
    Ocular Therapeutix, Inc., Bedford, MA
  • Footnotes
    Commercial Relationships Abbe Miller, Ocular Therapeutix, Inc. (E); Charles Blizzard, Ocular Therapeutix, Inc. (E); Amar Sawhney, Ocular Therapeutix (E); Michael Bassett, Ocular Therapeutix (E); Peter Jarrett, Ocular Therapeutix (E); Arthur Driscoll, Ocular Therapeutix (E); Monica O'Connor, Ocular Therapeutix (E); Doug Molla, Ocular Therapeutix (E); Steve Takach, Ocular Therapeutix (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5633. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Abbe Miller, Charles Blizzard, Amar Sawhney, Michael Bassett, Peter Jarrett, Arthur Driscoll, Monica O'Connor, Doug Molla, Steve Takach; Sustained Delivery of Travoprost from a Biodegradable Hydrogel Punctum Plug for the Treatment of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5633.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To formulate 1, 2 and 3-month sustained release travoprost from biodegradable hydrogel punctum plugs for the treatment of glaucoma.

 
Methods
 

Travoprost was encapsulated in various formulations of polylactide microparticles (PM), which were dry blended and suspended in a multi-arm polyethylene glycol (PEG) precursor solution conjugated with fluorescein and injected into small bore tubing prior to cross-linking. The travoprost in the PM/hydrogel matrix was dried in tubing and cut into plugs. Drug release rate from the respective formulations was assessed in PBS at pH 7.4 at 37 C until complete dissolution. The 3-month formulation was evaluated for plug visualization through the tissue in a canine model under illumination with a blue light and yellow filter.

 
Results
 

Sustained release of travoprost via PEG hydrogel punctum plugs was confirmed in vitro for each of the three formulations tested (Figure 1). Additionally, each formulation released a daily dose (based on in vitro release data) exceeding that administered by commercially available travoprost eye drops. Visualization and retention of the plug was confirmed in vivo (Figure 2).

 
Conclusions
 

1, 2 and 3-month sustained release of travoprost from biodegradable punctum plugs is feasible, and can deliver travoprost into the tear fluid at therapeutic levels. Plug retention is a key attribute to achieve clinical success, and confirmation of plug presence can be done by physicians and patients for monitoring. In recent clinical trials, the 1- and 2-month formulations demonstrated a reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension comparable to commercially available topical prostaglandin analogs.

     
Keywords: 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×